이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

P53 Y220C 돌연변이가 있는 진행성 고형 종양 환자에서 PC14586의 평가

2026년 10월 1일 업데이트: PMV Pharmaceuticals, Inc

P53 Y220C 돌연변이(PYNNACLE)가 있는 진행성 고형 종양 환자에서 PC14586의 안전성, 내약성, 약동학, 약력학 및 효능을 평가하기 위한 1/2상 오픈 라벨, 다기관 연구

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.

연구 개요

상태

모병

개입 / 치료

상세 설명

Rezatapopt is a first-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.

The primary objective of Phase 2 Monotherapy is to evaluate the efficacy of rezatapopt at the Recommended Phase 2 Dose (RP2D) including the Overall Response Rate (ORR) in the Ovarian Cancer Cohort and the ORR across all cohorts as determined by blinded independent central review. Secondary objectives of Phase 2 are to characterize the safety, pharmacokinetic (PK) properties, quality of life, and other efficacy measures of PC14586 rezatapopt at the RP2D. Enrollment is open for the Phase 2 Monotherapy portion of the study.

The primary objective of Phase 1 Monotherapy is to establish the maximum tolerated dose (MTD) and RP2D of rezatapopt. Secondary objectives are to characterize the PK properties, safety and tolerability, and to assess preliminary efficacy including ORR. Enrollment into Phase 1 Monotherapy is complete.

The primary objective of Phase 1b Combination Therapy is to establish the MTD/RP2D of rezatapopt when administered in combination with pembrolizumab. Secondary objectives of Phase 1b Combination Therapy are to characterize PK, safety and tolerability, and to assess preliminary efficacy of rezatapopt when administered in combination with pembrolizumab, including ORR. Enrollment into Phase 1b Combination Therapy is complete.

연구 유형

중재적

등록 (추정된)

300

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Seoul, 대한민국
        • 모병
        • Samsung Medical Center
        • 연락하다:
          • Chel Hun Choi, MD
      • Seoul, 대한민국
        • 모병
        • Asan Medical Center
        • 연락하다:
          • Dae Ho Lee, MD
      • Seoul, 대한민국
        • 모병
        • Seoul University Hospital
        • 연락하다:
          • Seock-Ah Im, MD
      • Seoul, 대한민국
        • 모병
        • Severance Hospital Yonsei University
        • 연락하다:
          • Jung-Yun Lee, MD
      • Seoul, 대한민국
        • 모병
        • National Cancer Center
        • 연락하다:
          • Myong Cheol Lim, MD, PhD
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, 독일
        • 모병
        • Nationale Centrum für Tumorerkrankungen (NCT) Heidelberg
        • 연락하다:
          • Martin Haag, MD
    • Bavaria
      • Augsburg, Bavaria, 독일
        • 모병
        • Universitätsklinikum Augsburg
        • 연락하다:
          • Rainer Claus, MD
    • Free and Hanseatic City of Hamburg
      • Hamburg, Free and Hanseatic City of Hamburg, 독일
        • 모병
        • Asklepios Klinik Altona
        • 연락하다:
          • Dirk Arnold, MD
    • Hesse
      • Frankfurt am Main, Hesse, 독일
        • 빼는
        • Universitätsklinikum Frankfurt
    • North Rhine-Westphalia
      • Essen, North Rhine-Westphalia, 독일
        • 모병
        • Universitätsklinikum Essen
        • 연락하다:
          • Marcel Wiesweg, MD
    • California
      • Irvine, California, 미국, 92868
        • 빼는
        • University of California Irvine Chao Family Comprehensive Cancer Center
      • La Jolla, California, 미국, 92093
        • 모병
        • University of San Diego Moores Cancer Center
        • 연락하다:
          • Shumei Kato, MD
      • Los Angeles, California, 미국, 90033
        • 모병
        • USC Norris Comprehensive Cancer Center
        • 연락하다:
          • Anthony El-Khoueiry, MD
      • Los Angeles, California, 미국, 90024
        • 모병
        • UCLA Jonsson Comprehensive Cancer Center
        • 연락하다:
          • Gottfried Konecny, MD
    • Colorado
      • Denver, Colorado, 미국, 80218
        • 모병
        • Rocky Mountain Cancer Center
        • 연락하다:
          • Allen Cohn, MD
    • Connecticut
      • New Haven, Connecticut, 미국, 06519
        • 모병
        • Yale Cancer Center
        • 연락하다:
          • Patricia LoRusso, MD
    • Delaware
      • Newark, Delaware, 미국, 19713
        • 모병
        • Medical Oncology Hematology Consultants
        • 연락하다:
          • Jamal Misleh, MD
    • Florida
      • Miami, Florida, 미국, 33136
        • 모병
        • University of Miami - Sylvester Comprehensive Cancer Center
        • 연락하다:
          • Gilberto de Lima Lopes Jr., MD
      • Orlando, Florida, 미국, 32803
        • 모병
        • Advent Health
        • 연락하다:
          • Robert Holloway, MD
      • Port Charlotte, Florida, 미국, 33980
        • 모병
        • Florida Cancer Specialists South
        • 연락하다:
          • Ivor Percent, MD
    • Massachusetts
      • Boston, Massachusetts, 미국, 02114
        • 모병
        • Massachusetts General Hospital
        • 연락하다:
          • Aparna Parikh, MD
      • Boston, Massachusetts, 미국, 02215
        • 모병
        • Dana Farber Cancer Institute
        • 연락하다:
          • Geoffrey Shapiro, MD, PhD
    • Michigan
      • Detroit, Michigan, 미국, 48201
        • 완전한
        • Karmanos Cancer Institute
    • New York
      • New York, New York, 미국, 10065
        • 모병
        • Memorial Sloan Kettering
        • 연락하다:
          • Alison Schram, MD
      • New York, New York, 미국, 10032
        • 아직 모집하지 않음
        • Columbia University Medical Center
        • 연락하다:
          • June Hou, MD
    • North Carolina
      • Durham, North Carolina, 미국, 27705
        • 모병
        • Duke University
        • 연락하다:
          • Niharika Mettu, MD, PhD
    • Ohio
      • Cleveland, Ohio, 미국, 44195
        • 모병
        • The Cleveland Clinic Taussig Cancer Center
        • 연락하다:
          • Dale Shepard, MD
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • 모병
        • University of Oklahoma
        • 연락하다:
          • Debra Richardson, MD
    • Oregon
      • Portland, Oregon, 미국, 97210
        • 모병
        • Oregon Health & Science University (OHSU)
        • 연락하다:
          • Shivaani Kummar, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19104
        • 모병
        • Abramson Cancer Center of the University of Pennsylvania
        • 연락하다:
          • Lainie Martin, MD
      • Pittsburgh, Pennsylvania, 미국, 15213
        • 모병
        • University of Pittsburgh Medical Center
        • 연락하다:
          • Sarah Taylor, MD, PhD
      • York, Pennsylvania, 미국, 17403
        • 모병
        • WellSpan York Cancer Center
        • 연락하다:
          • Ikechukwu Akunyili, MD
    • South Carolina
      • Charleston, South Carolina, 미국, 29425
        • 종료됨
        • Medical University of South Carolina
    • Tennessee
      • Nashville, Tennessee, 미국, 37203
        • 모병
        • Sarah Cannon Research Institute
        • 연락하다:
          • Melissa Johnson, MD
    • Texas
      • Austin, Texas, 미국, 78705
        • 모병
        • New Experimental Therapeutics - NEXT Oncology
        • 연락하다:
          • David Sommerhalder, MD
      • Bedford, Texas, 미국, 76022
        • 모병
        • Texas Oncology
        • 연락하다:
          • Terrence Wong, MD
      • Dallas, Texas, 미국, 75390
        • 모병
        • UT Southwest Simmons Cancer Center
        • 연락하다:
          • David Miller, MD
      • Houston, Texas, 미국, 77030
        • 모병
        • The University of Texas MD Anderson Cancer Center
        • 연락하다:
          • Ecaterina Dumbrava, MD
      • San Antonio, Texas, 미국, 78229
        • 모병
        • New Experimental Therapeutics of San Antonio - NEXT Oncology
        • 연락하다:
          • David Sommerhalder, MD
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • 모병
        • Virginia Cancer Specialists
        • 연락하다:
          • Alexander Spira, MD
    • Washington
      • Seattle, Washington, 미국, 98109
        • 모병
        • University of Washington, Fred Hutchinson Cancer Center
        • 연락하다:
          • Andrew Coveler, MD
    • Wisconsin
      • Madison, Wisconsin, 미국, 53705
        • 모병
        • University of Wisconsin Carbone Cancer Center
        • 연락하다:
          • Nataliya Uboha, MD, PhD
      • Barcelona, 스페인
        • 모병
        • NEXT Oncology-Hospital Quironsalud Barcelona
        • 연락하다:
          • Elena Garralda, MD
      • Barcelona, 스페인
        • 모병
        • Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON
        • 연락하다:
          • Lorena Farinas, MD
      • Madrid, 스페인, 28041
        • 모병
        • Hospital Universitario 12 de Octubre
        • 연락하다:
          • Santiago Ponce Aix, MD
      • Rioja, 스페인
        • 모병
        • START Rioja
        • 연락하다:
          • Jorge Luis Ramon Patino, MD
      • Valencia, 스페인
        • 모병
        • Hospital Clinico Universitario de Valencia
        • 연락하다:
          • José Alejandro Pérez Fidalgo, MD
    • Madrid
      • Madrid, Madrid, 스페인
        • 모병
        • START MADRID_Hospital Universitario Fundacion Jimenez Diaz
        • 연락하다:
          • Victor Moreno Garcia, MD
      • Madrid, Madrid, 스페인
        • 모병
        • START MADRID_Hospital Universitario HM Sanchinarro - CIOCC
        • 연락하다:
          • Irene Moreno, MD
      • Kent Ridge, 싱가포르
        • 모병
        • National University Hospital
        • 연락하다:
          • David Shao Peng Tan, MD
      • Singapore, 싱가포르, 168582
        • 모병
        • National Cancer Center of Singapore
        • 연락하다:
          • Tira Tan, MD
    • Middlesex
      • London, Middlesex, 영국
        • 모병
        • Sarah Cannon Research Institute UK
        • 연락하다:
          • Elisa Fontana, MD, PhD
    • Tyne and Wear
      • Newcastle upon Tyne, Tyne and Wear, 영국
        • 모병
        • Freeman Hospital
        • 연락하다:
          • Alastair Greystoke, MB ChB PhD
      • Milan, 이탈리아
        • 모병
        • Humanitas San Pio X
        • 연락하다:
          • Domenica Lorusso, MD
      • Naples, 이탈리아, 80131
        • 모병
        • IRCCS - lstituto Nazionale Tumori - Fondazione G. Pascale
        • 연락하다:
          • Anna Passarelli, MD
    • Lazio
      • Rome, Lazio, 이탈리아
        • 모병
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
        • 연락하다:
          • Anna Fagotti, MD
      • Rome, Lazio, 이탈리아
        • 모병
        • Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori Regina Elena
        • 연락하다:
          • Lorenza Landi, MD
    • Lombardy
      • Milan, Lombardy, 이탈리아
        • 모병
        • ASST Grande Ospedale Metropolitano Niguarda
        • 연락하다:
          • Salvatore Siena, MD
      • Milan, Lombardy, 이탈리아
        • 모병
        • Fondazione IRCCS Istituto Nazionale Dei Tumori
        • 연락하다:
          • Massimo Di Nicola, MD
      • Milan, Lombardy, 이탈리아
        • 모병
        • Istituto Europeo Di Oncologia
        • 연락하다:
          • Giuseppe Curigliano, MD
      • Rozzano, Lombardy, 이탈리아
        • 모병
        • Istituto Clinico Humanitas
        • 연락하다:
          • Armando Santoro, MD
    • Torino
      • Candiolo, Torino, 이탈리아
        • 모병
        • Fondazione del Piemonte per l'Oncologia (IRCCS)
        • 연락하다:
          • Chiara Lazzari, MD
      • Lyon, 프랑스
        • 모병
        • Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer
        • 연락하다:
          • Isabelle Ray-Coquard, MD
      • Nîmes, 프랑스, 30900
        • 모병
        • CHU de Nîmes
        • 연락하다:
          • Frédéric Fiteni, MD, PhD
      • Vandœuvre-lès-Nancy, 프랑스, 54519
        • 모병
        • Institute Cancer De Lorraine
        • 연락하다:
          • Aurélien Lambert, MD
    • Bas-Rhin
      • Strasbourg, Bas-Rhin, 프랑스
        • 모병
        • ICANS - Institut de cancérologie Strasbourg Europe
        • 연락하다:
          • Lauriane Eberst, MD
    • Gironde
      • Bordeaux, Gironde, 프랑스
        • 모병
        • Institut Bergonie
        • 연락하다:
          • Veronique Debien, MD
    • Haute-Garonne
      • Toulouse, Haute-Garonne, 프랑스
        • 모병
        • Institut Claudius Regaud
        • 연락하다:
          • Carlos-Alberto Gomez-Roca, MD
    • Loire-Atlantique
      • Saint-Herblain, Loire-Atlantique, 프랑스
        • 모병
        • EDOG Institut de Cancerologie de l'Ouest
        • 연락하다:
          • Jean-Sebastien Frenel, MD
    • Puy-de-Dôme
      • Clermont-Ferrand, Puy-de-Dôme, 프랑스
        • 모병
        • Centre Jean Perrin
        • 연락하다:
          • Xavier Durando, MD
    • Val-de-Marne
      • Villejuif, Val-de-Marne, 프랑스
        • 모병
        • Institut Gustave Roussy
        • 연락하다:
          • Yohann Loriot, MD
    • New South Wales
      • Camperdown, New South Wales, 호주
        • 모병
        • Chris O'Brien Lifehouse Hospital
        • 연락하다:
          • Peter Grimison, MD
    • Queensland
      • South Brisbane, Queensland, 호주
        • 모병
        • Mater Cancer Care Centre
        • 연락하다:
          • Catherine Shannon, MD
    • South Australia
      • Bedford Park, South Australia, 호주
        • 모병
        • Flinders Medical Center
        • 연락하다:
          • Shawgi Sukumaran, MD
    • Victoria
      • Clayton, Victoria, 호주
        • 모병
        • Monash Medical Centre
        • 연락하다:
          • Sophia Frentzas, MD
    • Western Australia
      • Nedlands, Western Australia, 호주
        • 모병
        • Linear Clinical Research
        • 연락하다:
          • Michael Millward, MD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

12년 이상 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval.
  • Locally advanced or metastatic solid malignancy with a TP53 Y220C mutation
  • Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
  • Previously treated with one or more lines of anticancer therapy and progressive disease
  • Adequate organ function
  • Measurable disease per RECIST v1.1 (Phase 2)

Additional Criteria for Inclusion in Phase 1b (rezatapopt) + pembrolizumab combination)

  • Anti-PD-1/PD-L1 naive or must have progressed on treatment
  • Measurable disease

Exclusion Criteria:

  • Anti-cancer therapy within 21 days (or 5 half-lives) of receiving the study drug
  • Radiotherapy within 14 days of receiving the study drug
  • Primary CNS tumor
  • History of leptomeningeal disease or spinal cord compression
  • Brain metastases, unless neurologically stable and do not require steroids to treat associated neurological symptoms
  • Stroke or transient ischemic attack within 6 months prior to screening
  • Heart conditions such as unstable angina within 6 months prior to screening, uncontrolled hypertension, a heart attack within 6 months prior to screening, congestive heart failure, prolongation of QT interval, or other rhythm abnormalities
  • Strong CYP3A4 inducers and strong CYP2C9 inhibitors/inducers within 14 days of first dose of rezatapopt
  • History of gastrointestinal (GI) disease that may interfere with absorption of study drug or patients unable to take oral medication
  • History of prior organ transplant
  • Known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer
  • Known, active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection

Additional Criteria for Exclusion from Phase 2 (rezatapopt monotherapy)

  • Known KRAS mutation, defined as a single nucleotide variant (SNV) (Phase 2). Exception: Ovarian cancer patients with a known KRAS SNV are permitted.

Additional Criteria for Exclusion from Phase 1b (rezatapopt) + pembrolizumab combination)

  • Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and discontinued from that treatment due to a Grade 3 or higher immune-related AE (irAE)
  • Received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention
  • Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy within 7 days prior to the first dose of study drug
  • Hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients
  • Active autoimmune disease that has required systemic treatment in past 2 years
  • History of radiation pneumonitis
  • History of (non-infectious) or active pneumonitis / interstitial lung disease that required steroids
  • Active infection requiring systemic therapy
  • Known history of HIV infection
  • Has previously received rezatapopt

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Phase 1 Monotherapy Dose Escalation

Multiple dose levels of daily oral rezatapopt will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of rezatapopt to recommend a Phase 2 dose (RP2D).

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

다른 이름들:
  • PC14586
실험적: Phase 1b Combination Therapy Dose Escalation, Part 1

Multiple dose levels of daily oral rezatapopt in combination with a stable dose of pembrolizumab (200 mg IV q3 weeks) will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 to recommend a Phase 2 dose (RP2D) of rezatapopt when administered in combination with pembrolizumab.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

다른 이름들:
  • PC14586

Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.

다른 이름들:
  • MK-3475
  • 키트루다®
  • 기조연설-D79
  • MK-3475-D79
실험적: Phase 1b Combination Therapy Dose Expansion, PD(L)-1 naive patients

Additional (expansion of) participants will enroll at the RP2D of daily oral PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 naive patients.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

다른 이름들:
  • PC14586

Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.

다른 이름들:
  • MK-3475
  • 키트루다®
  • 기조연설-D79
  • MK-3475-D79
실험적: Phase 1b Combination Therapy Dose Expansion, PD(L)-1 relapsed/refractory patients

Additional (expansion of) participants will enroll at the RP2D of daily oral rezatapopt when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 relapsed/refractory patients.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

다른 이름들:
  • PC14586

Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.

다른 이름들:
  • MK-3475
  • 키트루다®
  • 기조연설-D79
  • MK-3475-D79
실험적: Phase 2 Monotherapy Dose Expansion, Ovarian Cancer Cohort

Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Ovarian Cancer Cohort participants will have locally advanced or metastatic ovarian cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

다른 이름들:
  • PC14586
실험적: Phase 2 Monotherapy Dose Expansion, Lung Cancer Cohort

Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Lung Cancer Cohort participants will have locally advanced or metastatic lung cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

다른 이름들:
  • PC14586
실험적: Phase 2 Monotherapy Dose Expansion, Breast Cancer Cohort

Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Breast Cancer Cohort participants will have locally advanced or metastatic breast cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

다른 이름들:
  • PC14586
실험적: Phase 2 Monotherapy Dose Expansion, Endometrial Cancer Cohort

Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Endometrial Cancer Cohort participants will have locally advanced or metastatic endometrial cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

다른 이름들:
  • PC14586
실험적: Phase 2 Monotherapy Dose Expansion, Other Solid Tumors Cohort

Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Other Solid Tumors Cohort participants will have locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

다른 이름들:
  • PC14586

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt
기간: 40 months

Number of participants with treatment related adverse events

40 months
Phase 1 Monotherapy (Dose Escalation): Establish the Recommended Phase 2 Dose (RP2D)
기간: 30 months

RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data

30 months
Phase 1 Monotherapy (Dose Escalation): Establish the maximum tolerated dose (MTD) (Phase 1)
기간: The first 28 days of treatment (Cycle 1) per patient

Incidence of dose limiting toxicities (DLTs) during the first 28 days of treatment with rezatapopt

The first 28 days of treatment (Cycle 1) per patient
Phase 1b Combination Therapy (Part 1: Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt when administered in combination with pembrolizumab
기간: 18 months for treatment arm

Number of participants with treatment related adverse events

18 months for treatment arm
Phase 1b Combination Therapy (Part 1: Dose Escalation): Establish the maximum tolerated dose (MTD) of rezatapopt when administered in combination with pembrolizumab
기간: The first 28 days of combination treatment arm (starting on Day -7) per patient

Incidence of dose limiting toxicities (DLTs) during the first 28 days of treatment with rezatapopt

The first 28 days of combination treatment arm (starting on Day -7) per patient
Phase 1b Combination Therapy (Part 1: Dose Escalation): Establish the Recommended Phase 2 Dose (RP2D) of rezatapopt when administered in combination with pembrolizumab
기간: 18 months

RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data

18 months
Phase 1b Combination Therapy (Part 2: Dose Expansion): Determine the number and type of adverse events to characterize the safety of rezatapopt when administered in combination with pembrolizumab
기간: 12 months for treatment arm

Number of participants with treatment related adverse events

12 months for treatment arm
Phase 2 Monotherapy (Dose Expansion): Response rate assessment to evaluate the clinical activity / efficacy of rezatapopt
기간: 34 months

Overall response rate in accordance with Response Evaluation Criteria (RECIST) v.1.1 as assessed by independent review across all cohorts

34 months
Phase 2 Monotherapy (Dose Expansion): Response rate assessment to evaluate the clinical activity / efficacy of rezatapopt in ovarian cancer patients
기간: 34 months

Overall response rate in accordance with Response Evaluation Criteria (RECIST) v.1.1 as assessed by independent review in the ovarian cancer cohort

34 months

2차 결과 측정

결과 측정
측정값 설명
기간
Phase 1 Monotherapy: PK profile of rezatapopt - Peak concentration (Cmax)
기간: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 1 Monotherapy: PK profile of rezatapopt - Time of peak concentration (Tmax)
기간: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 1 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve from time zero to time of last sampling timepoint (AUC0-t)
기간: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 1 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve in one dosing interval (AUCtau)
기간: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 1 Monotherapy: PK profile of rezatapopt - Trough observed concentrations (Ctrough/Ctau)
기간: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 1 Monotherapy: Blood plasma assessment to describe the concentration of PC14586 and metabolites when rezatapopt is administered orally.
기간: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Blood plasma concentration

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 1 Monotherapy (Dose Escalation): Overall Response Rate per RECIST v1.1 or PCWG3 modified RECIST v1.1
기간: 41 months for study (end of Phase 1)

Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent

41 months for study (end of Phase 1)
Phase 1 Monotherapy (Dose Escalation): Time to Response per RECIST v1.1 or PCWG3 modified RECIST v1.1
기간: 41 months for study (end of Phase 1)

Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent

41 months for study (end of Phase 1)
Phase 1 Monotherapy (Dose Escalation): Duration of Response per RECIST v1.1 or PCWG3 modified RECIST v1.1
기간: 41 months for study (end of Phase 1)

Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent

41 months for study (end of Phase 1)
Phase 1 Monotherapy (Dose Escalation): Disease Control Rate per RECIST v1.1 or PCWG3 modified RECIST v1.1
기간: 41 months for study (end of Phase 1)

Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent

41 months for study (end of Phase 1)
Phase 1 Monotherapy (Dose Escalation): Progression Free Survival per RECIST v1.1 or PCWG3 modified RECIST v1.1
기간: 41 months for study (end of Phase 1)

Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent

41 months for study (end of Phase 1)
Phase 1 Monotherapy (Dose Escalation): Overall Survival
기간: 41 months for study (end of Phase 1)

Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent

41 months for study (end of Phase 1)
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Peak concentration (Cmax)
기간: Approximately 12 months per patient (30 months for treatment arm)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (30 months for treatment arm)
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Time of peak concentration (Tmax)
기간: Approximately 12 months per patient (30 months for treatment arm)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (30 months for treatment arm)
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Area under the plasma concentration-time curve from time zero to time of last sampling timepoint (AUC0-t)
기간: Approximately 12 months per patient (30 months for treatment arm)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (30 months for treatment arm)
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Area under the plasma concentration-time curve in one dosing interval (AUCtau)
기간: Approximately 12 months per patient (30 months for treatment arm)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (30 months for treatment arm)
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Trough observed concentrations (Ctrough/Ctau)
기간: Approximately 12 months per patient (30 months for treatment arm)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (30 months for treatment arm)
Phase 1b Combination Therapy: Blood plasma assessment to describe the concentration of rezatapopt and metabolites when rezatapopt is administered orally in combination with pembrolizumab.
기간: Approximately 12 months per patient (30 months for treatment arm)

Blood plasma concentration

Approximately 12 months per patient (30 months for treatment arm)
Phase 1b Combination Therapy: Overall Response Rate per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review
기간: 30 months for study (end of Phase 1b)

Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab

30 months for study (end of Phase 1b)
Phase 1b Combination Therapy: Time to Response per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review
기간: 30 months for study (end of Phase 1b)

Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab

30 months for study (end of Phase 1b)
Phase 1b Combination Therapy: Duration of Response per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review
기간: 30 months for study (end of Phase 1b)

Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab

30 months for study (end of Phase 1b)
Phase 1b Combination Therapy: Disease Control Rate per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review
기간: 30 months for study (end of Phase 1b)

Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab

30 months for study (end of Phase 1b)
Phase 1b Combination Therapy: Overall Survival
기간: 30 months for study (end of Phase 1b)

Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab

30 months for study (end of Phase 1b)
Phase 1b Combination Therapy: Determine the number and type of adverse events to characterize the safety of rezatapopt
기간: 30 months for study (end of Phase 1b)

Number of participants with treatment related adverse events

30 months for study (end of Phase 1b)
Phase 1b Combination Therapy: Progression Free Survival per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review
기간: 30 months for study (end of Phase 1b)

Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab

30 months for study (end of Phase 1b)
Phase 2 Monotherapy: PK profile of rezatapopt - Time of peak concentration (Tmax)
기간: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 2 Monotherapy: PK profile of rezatapopt - Peak concentration (Cmax)
기간: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 2 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve from time zero to time of last sampling timepoint (AUC0-t)
기간: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 2 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve in one dosing interval (AUCtau)
기간: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 2 Monotherapy: PK profile of rezatapopt - Trough observed concentrations (Ctrough/Ctau)
기간: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 2 Monotherapy: Blood plasma assessment to describe the concentration of rezatapopt and metabolites when rezatapopt is administered orally.
기간: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Blood plasma concentration

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 2 Monotherapy (Dose Expansion): Determine the number and type of adverse events to characterize the safety of rezatapopt
기간: 34 months for study (end of Phase 2)

Number of participants with treatment related adverse events

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Overall Response Rate across all cohorts per RECIST v1.1 as assessed by Investigator
기간: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Overall Response Rate in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator
기간: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Time to Response in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review
기간: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Time to Response across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review
기간: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Duration of Response in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review
기간: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Duration of Response across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review
기간: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Disease Control Rate in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review
기간: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Disease Control Rate across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review
기간: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Progression Free Survival in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review
기간: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Progression Free Survival across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review
기간: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Overall Survival in ovarian cancer cohort
기간: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Overall Survival across all cohorts
기간: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Quality of life assessment
기간: Evaluated at every visit. 34 months for treatment arm (end of Phase 2)

Changes from baseline in quality of life as measured by a validated instrument, for participants 18 and older

Evaluated at every visit. 34 months for treatment arm (end of Phase 2)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 연구 책임자: Marc Fellous, MD, Sr. Vice President, Clinical Development and Medical Affairs

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 10월 29일

기본 완료 (추정된)

2026년 12월 15일

연구 완료 (추정된)

2027년 12월 31일

연구 등록 날짜

최초 제출

2020년 10월 1일

QC 기준을 충족하는 최초 제출

2020년 10월 7일

처음 게시됨 (실제)

2020년 10월 14일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 2일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 1일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • PMV-586-101
  • KEYNOTE-D79 (레지스트리 식별자: Merck, Sharp & Dohme, LLC)
  • MK-3475-D79 (레지스트리 식별자: Merck, Sharp & Dohme, LLC)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .